CRISPR-Cas12a2 Targets Mutant Cancer Transcripts for Selective Cell Death

“Restoring p53 function for tumour regression has been considered the 'holy grail' of cancer therapy. However, no approved therapies are available to target the p53 protein due to its lack of druggable pockets and the difficulty of activating defective transcription factors”Zeng et al.

A study published this week in Nature from Jennifer Doudna's laboratory at UC Berkeley and her collaborators proposes a fundamentally different approach – one that bypasses the protein entirely and uses the mutant transcript as both a sensor and a trigger for selective cancer cell death.

The work follows a Nature study published in May by Paul Scholz and colleagues, who first demonstrated RNA-triggered cell killing by Cas12a2 in eukaryotic cells. CRISPR-Cas12a2 is a bacterial nuclease that normally functions as part of an abortive infection system: when a foreign RNA is detected, the enzyme enters an indiscriminate trans-cleavage mode, degrading cellular nucleic acids to induce dormancy or death. In the new study, Zeng and colleagues extended the concept by applying it to clinically relevant cancer mutations.

By programming Cas12a2 with guide RNAs complementary to cancer-specific transcripts, they showed that the enzyme, once activated by its RNA target, shreds eukaryotic chromatin in trans-triggering DNA damage responses, cell cycle arrest, and ultimately cell death. The elegance lies in what it does not require: no druggable protein pocket, no restored function, no correction of the underlying mutation. The mutant transcript itself becomes the kill switch.

»Restoring p53 function for tumour regression has been considered the 'holy grail' of cancer therapy. However, no approved therapies are available to target the p53 protein due to its lack of druggable pockets and the difficulty of activating defective transcription factors,« the authors state in the Nature paper.

Mutant transcripts become the target

The clinical rationale is particularly compelling for TP53. Unlike tumour suppressors that are simply lost, TP53 mutations tend to be clonal – arising early in tumour evolution and persisting across the heterogeneous cell population. Nearly all tumour cells driven by TP53 mutations therefore retain and express the mutant transcript, making it a stable and near-universal target within a given tumour.

A strategy that kills cells precisely because they express the mutant transcript sidesteps the restoration problem altogether – and may also avoid a key dose-limiting toxicity of p53-activating approaches, where non-targeted activation in healthy tissue can induce senescence and whole-genome duplication.

“By targeting these ubiquitous mutant transcripts, Cas12a2 could overcome tumour heterogeneity”Zeng et al.

The selectivity data are striking. Using cells engineered to express common TP53 hotspot mutations, the team identified guide RNAs that induce robust growth arrest at sub-nanomolar concentrations while leaving wild-type cells unaffected. Single-nucleotide discrimination was confirmed both in cell-based dose-response experiments and in biochemical assays, where trans DNA cleavage was approximately 28-fold faster in the presence of mutant target RNA than wild-type RNA.

In a competitive growth assay approximating the clinical scenario of tumour cells embedded in normal tissue, mutant cells were selectively depleted while wild-type cells were permitted to dominate the population. The approach extends beyond point mutations: EGFR exon 19 deletion mutations, common in non-small cell lung cancer, were targeted with similar precision using a guide RNA complementary to the mutant deletion junction sequence.

»By targeting these ubiquitous mutant transcripts, Cas12a2 could overcome tumour heterogeneity,« the authors write.

Most TP53 mutations may be within reach

A bioinformatic analysis of TP53 mutations across more than 16,700 patient samples suggests that the majority of clinically encountered mutations may be amenable to this approach, either through direct protospacer flanking site activation or through adjacent adenine motifs that could support targeting via protospacer mismatches. This breadth of potential coverage is one of the more consequential aspects of the paper, given the size of the patient population involved.

The in vivo data, generated using lipid nanoparticle delivery of Cas12a2 mRNA and guide RNA, are encouraging but carry important caveats. In both a liver tumour model targeting the MYC oncogene and a lung tumour model using TP53-mutant NSCLC cells, treatment produced statistically significant reductions in tumour burden in early-stage settings. In a more demanding late-stage lung tumour model, primary tumour burden was not reduced, though treated animals showed delayed metastasis formation. Histological analysis showed no obvious tissue damage in any treatment group.

“As the first approach to precisely target specific TP53 mutations, our work paves the way for a new class of precision therapies using RNA-guided CRISPR nucleases”Zeng et al.

The delivery efficiency – assessed at roughly 7-18% of tumour cells in the lung xenograft model – is modest and will need to improve for clinical translation. The observation that tumours from treated mice showed significantly reduced TP53 expression points to transcript downregulation as a potential resistance mechanism, which the authors propose could be addressed through multiplexed targeting of several cancer-associated transcripts simultaneously. Cas12a2 is capable of processing its own CRISPR array, potentially enabling co-delivery of multiple guides from a single payload.

Delivery and safety questions remain

Several uncertainties remain. Guide RNA design rules for Cas12a2 in human cells are incompletely defined, the immunogenicity of the bacterial protein in humans has not been addressed, and the question of trans-cleavage activity in normal bystander cells exposed to LNPs non-specifically is an open safety consideration. The magnesium dependence of Cas12a2 may also introduce variability across different tumour microenvironments.

»No approved methods exist to directly target TP53 mutations, leaving a critical gap given TP53's importance in cancer. As the first approach to precisely target specific TP53 mutations, our work paves the way for a new class of precision therapies using RNA-guided CRISPR nucleases,« the authors conclude.

What the paper establishes is a proof of principle with unusual conceptual clarity. Transcript-activated chromatin shredding does not attempt to fix what is broken in a cancer cell – it turns the molecular signature of malignancy into the mechanism of its own destruction. Whether that principle can be translated into a clinical therapy will depend on advances in delivery, safety characterisation, and guide design. But the underlying logic is sufficiently compelling, and the selectivity data sufficiently granular, to mark this as a meaningful step toward addressing a problem that has resisted solution for thirty years.

The study was led by Jingkun Zeng and Jennifer A. Doudna from University of California, Berkeley and it was published in Nature on 8 June 2026. The earlier study led by Paul Scholz at Akribion Therapeutics in Zwingenberg, Germany was published in Nature on 6 May 2026.